Idiopathic pulmonary fibrosis digest – 2021 Idiopathic pulmonary fibrosis digest – 2021 United Therapeutics enrolled first patient in Phase 3 TETON study Tyvaso (Treprostinil (inhaled), Epoprostenol receptor agonist/ platelet aggregation inhibitor) – United Therapeutics/ Ascendis Pharma/ Ferrer/ Lee’s Pharmaceutical/ Mochida […]
Idiopathic pulmonary fibrosis digest – 2021 Idiopathic pulmonary fibrosis digest – 2021 Liminal BioSciences to complete pharmacokinetic studies with Fezagepras before initiating Phase 2 study Fezagepras (FFAR1/ PPAR alpha modulator) – Liminal BioSciences Liminal BioSciences stopped its plans to move […]
Idiopathic pulmonary fibrosis digest – 2021 Idiopathic pulmonary fibrosis digest – 2021 Early result of Daewoong’s DWN12088 in idiopathic pulmonary fibrosis DWN12088 (PRS-inhibitor) – Daewoong Pharmaceutical Trial details: ACTRN12619001239156; Phase 1 in healthy volunteers; N= 80; Cohort 1: single-ascending dose […]
Idiopathic pulmonary fibrosis digest – 2021 Idiopathic pulmonary fibrosis digest – 2021 Avalyn Pharmaceuticals’ inhaled pirfenidone showed promising Phase 1/2 data Avalyn Pharmaceuticals reported results of Phase 1/2 inhaled Pirfenidone in idiopathic pulmonary fibrosis AP01 (Aerosolized Pirfenidone, Collagen and cytokine […]
